Literature DB >> 16731144

Thromboxane receptor stimulation suppresses guanylate cyclase-mediated relaxation of radial arteries.

Muhammad Arshad1, Venkataramana Vijay, Beverly C Floyd, Brian Marks, Mohan R Sarabu, Michael S Wolin, Sachin A Gupte.   

Abstract

BACKGROUND: The internal mammary artery (IMA) and the radial artery (RA) are routinely used in coronary artery bypass grafting. However, RA grafts have a higher incidence of postoperative vasospasm and comparatively poor patency rates. The present study was undertaken to investigate the signaling pathways mediating contraction and relaxation in the IMA and RA with the aim of better understanding the mechanism underlying the propensity of RA grafts to spasm.
METHODS: We examined the contractile responses of the IMA and RA to KCl (a depolarizing agent), phenylephrine (an alpha-adrenergic agonist), and U46619 (a thromboxane analogue).
RESULTS: Contractions induced by KCl or U46619 did not significantly differ in IMA and RA. By contrast, phenylephrine evoked significantly greater contraction of the IMA than the RA. Contractions induced by both phenylephrine and U46619 were dose-dependently inhibited by nifedipine (an L-type calcium channel blocker). Estimation of thromboxane A2 (TxA2) and prostacyclin (PGI2) synthesis revealed that the TxA2 to PGI2 ratio in the RA was twice that in the IMA. Moreover, acetylcholine-induced and nitroglycerin-induced relaxation of RA precontracted with U46619 was significantly impaired, as compared with RA precontracted with phenylephrine. These data suggest that inhibition of nitroglycerin-induced soluble guanylate cyclase activity by U46619 was at least partially responsible for the diminished vasodilatory response of RA to nitric oxide.
CONCLUSIONS: Our findings suggest that by reducing nitric oxide-stimulated soluble guanylate cyclase activity, the higher TxA2 to PGI2 ratios in RA, and the elevated serum TxA2 levels seen during coronary artery bypass grafting operations, may underlie the vasospasm and poor patency rates seen with the RA.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16731144     DOI: 10.1016/j.athoracsur.2006.01.024

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  5 in total

1.  Functional changes in the uterine artery precede the hypertensive phenotype in a transgenic model of hypertensive pregnancy.

Authors:  Victor M Pulgar; Liliya M Yamaleyeva; Jasmina Varagic; Carolynne McGee; Michael Bader; Ralf Dechend; K Bridget Brosnihan
Journal:  Am J Physiol Endocrinol Metab       Date:  2015-09-22       Impact factor: 4.310

2.  Peroxide generation by p47phox-Src activation of Nox2 has a key role in protein kinase C-induced arterial smooth muscle contraction.

Authors:  Sachin A Gupte; Pawel M Kaminski; Shimran George; Lioubov Kouznestova; Susan C Olson; Rajamma Mathew; Thomas H Hintze; Michael S Wolin
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-01-23       Impact factor: 4.733

3.  Beneficial In Vitro Effects of a Low Myo-Inositol Dose in the Regulation of Vascular Resistance and Protein Peroxidation under Inflammatory Conditions.

Authors:  Agata Rolnik; Beata Olas; Joanna Szablińska-Piernik; Lesław Bernard Lahuta; Andrzej Rynkiewicz; Piotr Cygański; Katarzyna Socha; Leszek Gromadziński; Michael Thoene; Michał Majewski
Journal:  Nutrients       Date:  2022-03-07       Impact factor: 5.717

4.  Type III Kounis Syndrome Secondary to Ciprofloxacin-Induced Hypersensitivity.

Authors:  Alberto Navarro-Navajas; Ingrid Casallas; Daniel Isaza; Paola Ortiz; Daniela Baracaldo-Santamaría; Carlos-Alberto Calderon-Ospina
Journal:  Medicina (Kaunas)       Date:  2022-06-26       Impact factor: 2.948

5.  Glucose-6-phosphate dehydrogenase and NADPH redox regulates cardiac myocyte L-type calcium channel activity and myocardial contractile function.

Authors:  Dhwajbahadur K Rawat; Peter Hecker; Makino Watanabe; Sukrutha Chettimada; Richard J Levy; Takao Okada; John G Edwards; Sachin A Gupte
Journal:  PLoS One       Date:  2012-10-05       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.